|
|
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4507-4511.
Prepublished online as a Blood First Edition Paper on August 8, 2008; DOI 10.1182/blood-2008-04-152967.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS AND STEM CELLS
Brief Report
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations
Oliver Tunstall-Pedoe1,
Anindita Roy1,
Anastasios Karadimitris1,
Josu de la Fuente1,
Nicholas M. Fisk2,
Phillip Bennett2,
Alice Norton3,
Paresh Vyas3, and
Irene Roberts1
1 Department of Haematology and
2 Institute of Reproductive and Developmental Biology, Imperial College London and Imperial Healthcare NHS Trust, London; and
3 MRC Molecular Haematology Unit and Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
Down syndrome (DS) children have a high frequency of acute megakaryoblastic leukemia (AMKL) in early childhood. At least 2 in utero genetic events are required, although not sufficient, for DS-AMKL: trisomy 21 (T21) and N-terminal–truncating GATA1 mutations. To investigate the role of T21 in DS-AMKL, we compared second trimester hemopoiesis in DS without GATA1 mutations to gestation-matched normal controls. In all DS fetal livers (FLs), but not marrows, megakaryocyte-erythroid progenitor frequency was increased (55.9% ± 4% vs 17.1% ± 3%, CD34+CD38+ cells; P < .001) with common myeloid progenitors (19.6% ± 2% vs 44.0% ± 7%) and granulocyte-monocyte (GM) progenitors (15.8% ± 4% vs 34.5% ± 9%) commensurately reduced. Clonogenicity of DS-FL versus normal FL CD34+ cells was markedly increased (78% ± 7% vs 15% ± 3%) affecting megakaryocyte-erythroid ( 7-fold higher) and GM and colony-forming unit–granulocyte, erythrocyte macrophage, megakaryocyte (CFU-GEMM) progenitors. Replating efficiency of CFU-GEMM was also markedly increased. These data indicate that T21 itself profoundly disturbs FL hemopoiesis and they provide a testable hypothesis to explain the increased susceptibility to GATA1 mutations in DS-AMKL and DS-associated transient myeloproliferative disorder.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Trisomy 21 tilts the balance
- Shai Izraeli
Blood 2008 112: 4361-4362.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. C. Cabelof, H. V. Patel, Q. Chen, H. van Remmen, L. H. Matherly, Y. Ge, and J. W. Taub
Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome
Blood,
September 24, 2009;
114(13):
2753 - 2763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Xavier, Y. Ge, and J. W. Taub
Down Syndrome and Malignancies: A Unique Clinical Relationship: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2009;
11(5):
371 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Salek-Ardakani, G. Smooha, J. de Boer, N. J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H. J.M. Brady
ERG Is a Megakaryocytic Oncogene
Cancer Res.,
June 1, 2009;
69(11):
4665 - 4673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. K. Wiseman, K. A. Alford, V. L.J. Tybulewicz, and E. M.C. Fisher
Down syndrome--recent progress and future prospects
Hum. Mol. Genet.,
April 15, 2009;
18(R1):
R75 - R83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet.,
April 15, 2009;
18(R1):
R84 - R93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Malinge, S. Izraeli, and J. D. Crispino
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Blood,
March 19, 2009;
113(12):
2619 - 2628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
